27 Mar 2014 08:00
For immediate release | 27 March 2014 |
ABCAM PLC
("Abcam" or "the Company")
Appointment of Non-Executive Director
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of innovative protein research tools, is pleased to announce the appointment of Lady Louise Patten as a Non-Executive Director of the Company and as Chair of the Remuneration Committee with immediate effect.
Louise brings extensive board level and corporate governance experience, having served on quoted company boards for more than 20 years as a non-executive director, senior independent director, remuneration committee chair and company chair at businesses including the retailer Marks & Spencer plc, retailing group GUS plc and hotelier Hilton Group plc.
Louise is currently a non-executive director of the FTSE-250 property group Intu Properties plc. She is also a senior adviser at the management consultancy Bain & Company and a non-executive director at the privately held risk consultancy Control Risks Group, where she chairs the audit committee.
Mike Redmond, Abcam's Chairman, said: "I'm delighted to welcome Louise Patten to Abcam as an independent Non-Executive Director. Louise has extensive business and corporate governance experience gained at substantial organisations. I am particularly pleased to welcome Louise as Abcam's first female Board member. We look forward to her input to the Board."
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Lady Louise Alexandra Virginia Patten, age 60 years, has been a director of the following companies during the five years preceding the date of this announcement:
Current directorships | Past directorships |
Intu Properties plc | Brixton plc |
Control Risks Group Holdings Limited | Marks & Spencer plc |
UK Asset Resolution Limited | |
Bradford & Bingley plc | |
Northern Rock (Asset Management) plc |
There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
For further information please contact:
Abcam |
+ 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Clare Terlouw / Jock Maxwell MacDonald | |
Buchanan |
+ 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 130,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices and ships to over 100 countries. The Company was founded in 1998 and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com